Kenvue announced May 2 that its near-term greenhouse gas emissions (GHG) reduction targets were validated by the Science Based Targets initiative (SBTi).

Spun off from Johnson & Johnson last year, NJBIZ recently chronicled the latest chapter of the world’s largest pure-play consumer health company’s next chapter. Last month, the maker of Aveeno and Tylenol celebrated a groundbreaking for a new headquarters in Summit.

Kenvue says the validated near-term targets are part of the company’s Healthy Lives Mission, its environmental, social, and governance strategy; marking its commitment to setting long-term net zero emissions targets informed by the SBTi Net Zero Standard.

The Kenvue near-term targets validated by SBTi include commitments:

• To reduce absolute Scope 1 and 2 GHG emissions 42% by 2030, from a 2020 base year;
• That 75% of its suppliers by emissions covering purchased goods and services as well as upstream transportation and distribution will have science-based targets by 2028.

In a press release, Pamela Gill-Alabaster, global head of ESG and sustainability at Kenvue, stressed the company’s recognition of the increasingly detrimental impact that climate change is having on people and ecosystems around the world.

“As a company dedicated to a healthy future, we are setting ambitious science-based emissions reduction targets and action plans to decarbonize our products, operations, and value chain,” said Gill-Alabaster. “We are proud that the SBTi has validated our climate targets so early in our new company’s journey – and this important milestone signals our intent to create a positive change and make meaningful progress in support of our Healthy Lives Mission.”

See also:

Hackensack Meridian Health is furthering its longstanding commitment to a healthier, more sustainable community with a groundbreaking, multiyear solar energy initiative. Click here to read more about the new partnership.